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GUEST EDITORIAL
There has been a significant rise in the burden of 
non-communicable diseases (NCDs) in the past 20 
years.[1] Atherosclerotic peripheral arterial disease 
(PAD) is one of the most prevalent, morbid and 
mortal of all the NCDs, with more than 202 million 
people, conservatively estimated, affected by PAD.[2] This is about 
six times the 34 million people estimated to be living with HIV 
at the end of 2011.[3] PAD does not only affect high-income 
countries. As population demographics change in low- and middle-
income countries, patients are exposed to the sustained effects of 
exposure to the risk factors of smoking, hypertension, diabetes and 
dyslipidaemia.[2] PAD also affects both young and old individuals in 
low- and high-income countries. Globally, there has been an increase 
of about 24% in PAD from 2000 to 2010.[3] This rise in prevalence 
comes at a significant cost, as many low- and middle-income 
countries are combating the scourges of numerous debilitating 
communicable diseases.
The risk of ischaemic stroke increases by a factor of 1.5 for every 
10 years of increase in age.[4] The increased prevalence of heart failure, 
hypertension and atrial fibrillation (AF) in the older population 
explains the rising incidence of stroke with age. Over the age of 85 
years, the prevalence of AF is as high as 10%, and 25% of strokes in 
patients >80 years of age are attributable to AF.[5,6] The absolute effect 
of intervention with anticoagulation using warfarin in the elderly is 
far greater than in younger patients owing to the greater incidence of 
AF in the former population group.[7]
As with AF, so too does the prevalence of deep vein thrombosis 
(DVT) or pulmonary embolus (PE) increase with age. In those 
<50 years old, the incidence of a new DVT or PE is about 1/1 000 
person-years, but this rises dramatically to 6/1 000 person-years 
in patients >80 years old.[8] For a number of years intervention 
and anticoagulation have been utilised to modify future risk.[9] 
DVT prophylaxis is important, especially in patients undergoing 
major orthopaedic surgery, who represent a high-risk group for the 
development of DVTs and PEs. The novel anticoagulants, which 
show some promise for the prevention of thrombotic complications 
of surgery, have been studied extensively in this group of patients.
Warfarin and multiple other drugs are attractive therapeutic 
agents to limit the damages of numerous vascular NCDs, and their 
development has broadened our understanding of homoeostasis. 
These anticoagulants are not without side-effects, which may carry 
a significant morbidity and mortality. The vascular NCDs affect the 
disciplines of general and orthopaedic surgery, internal medicine 
and general practice worldwide. These diseases, and the agents used 
to manage them, are an evolving field, which has shown many rapid 
advances during the last 15 years. As newer anticoagulants come to 
the market, their advantages and disadvantages need to be explored 
to clearly define the niche which these often expensive agents 
occupy. Clearly, the convenience afforded 
by the newer agents is novel and exciting 
when compared with the more traditional 
vitamin K antagonists (VKAs), but this 
advantage will need to be weighed up 
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